Skip to main content

Advertisement

ADVERTISEMENT

Psoriatic Arthritis News

News
12/15/2023
Hannah Musick
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide...
12/15/2023
First Report Managed Care
News
11/15/2023

Lisa Kuhns, PhD

Lisa Kuhns, PhD
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
10/24/2023

Danielle Sposato

Danielle Sposato
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good...
10/24/2023
First Report Managed Care

Advertisement

News
09/12/2023
Jolynn Tumolo
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that...
09/12/2023
First Report Managed Care
News
08/22/2023
Jolynn Tumolo
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with...
08/22/2023
First Report Managed Care
News
07/27/2023
Jolynn Tumolo
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a...
07/27/2023
First Report Managed Care

Advertisement

News
06/16/2023
Jolynn Tumolo
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that...
06/16/2023
First Report Managed Care
News
05/18/2023
Jolynn Tumolo
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation...
05/18/2023
First Report Managed Care
News
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care

Advertisement

News
03/16/2023
Jolynn Tumolo
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the...
03/16/2023
First Report Managed Care

Advertisement